The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.131.9.1027

The authors conducted a post hoc comparison of two very similar doxepin studies that included outpatients with mixed anxiety and depression. The first study used a three-times-a-day schedule, and the second used a bedtime schedule. All differences between the two treatments favored the bedtime regimen. Although the reports cannot take the place of a direct comparison between the two dosage schedules, they offer evidence for the usefulness and value of single-dose bedtime medication for anxious-depressed outpatients receiving doxepin treatment.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.